Daily Stock Analysis, TBPH, Theravance Biopharma Inc, priceseries

Theravance Biopharma Inc. Daily Stock Analysis
Stock Information
Open
9.47
Close
9.68
High
9.84
Low
9.38
Previous Close
9.61
Daily Price Gain
0.07
YTD High
13.17
YTD High Date
Jan 10, 2022
YTD Low
7.71
YTD Low Date
Jan 24, 2022
YTD Price Change
-2.60
YTD Gain
-21.17%
52 Week High
22.74
52 Week High Date
Apr 22, 2021
52 Week Low
6.10
52 Week Low Date
Sep 15, 2021
52 Week Price Change
-9.63
52 Week Gain
-49.87%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 18. 2017
37.52
May 3. 2017
39.49
11 Trading Days
5.24%
Link
LONG
Aug 23. 2017
27.78
Sep 1. 2017
30.05
7 Trading Days
8.16%
Link
LONG
Jul 3. 2018
23.68
Jul 18. 2018
25.68
10 Trading Days
8.45%
Link
LONG
Sep 20. 2018
28.15
Oct 8. 2018
32.82
12 Trading Days
16.58%
Link
LONG
Jul 22. 2019
18.10
Aug 6. 2019
19.37
11 Trading Days
7.02%
Link
LONG
Nov 20. 2019
17.60
Dec 11. 2019
20.76
14 Trading Days
17.98%
Link
LONG
Dec 12. 2019
21.07
Jan 2. 2020
24.11
13 Trading Days
14.41%
Link
LONG
Jan 23. 2020
25.86
Feb 11. 2020
29.09
13 Trading Days
12.51%
Link
LONG
Apr 8. 2020
23.50
May 1. 2020
28.20
16 Trading Days
20.01%
Link
LONG
Dec 7. 2021
8.54
Jan 11. 2022
11.80
24 Trading Days
38.15%
Link
Company Information
Stock Symbol
TBPH
Exchange
NasdaqGM
Company URL
http://www.theravance.com
Company Phone
650-808-6000
CEO
Rick E. Winningham
Headquarters
-
Business Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CAYMAN ISLANDS KY1-1104
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001583107
About

Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule medicines. It operates through the following geographical segments: the Unites States, Europe, Asia, and Other. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded on July 2013 and is headquartered in George Town, Cayman Islands.

Description

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.